Clene Inc. Stock News

Upgrades For First Interstate BancSystem Inc (NASDAQ:FIBK), Keefe, Bruyette & Woods upgraded the previous rating of Market Perform to Outperform. For the first quarter, First Interstate BancSys had an

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Results show significant survival benefit in participants who entered open-label extension of study of CNM-Au8®, a gold nanocrystal suspension, compared to validated ENCALS prediction mode Results sh

Clene Inc (NASDAQ: CLNN ) has announced multiple presentations of updated clinical trial results from the Phase 2 RESCUE-ALS and REPAIR trials at the 2022 MDA Clinical & Scientific Conference. RESCUE-ALS Phase 2 trial examined the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in 45 … Full story available on Benzinga.com

Analyses of long-term open-label extension of RESCUE-ALS trial indicate improved survival compared to predictions derived from validated ENCALS risk model Interim results demonstrate approximately 70% decreased risk of death for participants who entered the RESCUE-ALS long-term open label extension SALT LAKE CITY, March 14, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN ) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced multiple presentations of updated clinical trial results from the Phase 2 RESCUE-ALS and REPAIR trials in addition to new mechanistic preclinical data in ALS at the 2022 MDA Clinical & Scientific Conference, taking place March 13-16 in Nashville. The first poster, titled " RESCUE-ALS Trial Results: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in ALS ," selected as an oral presentation, and the second poster, " Evidence for a Potential Survival Benefit with CNM-Au8 Treatment from the RESCUE-ALS Trial Long-Term Open Label Extension," further support Clene''s lead drug candidate CNM-Au8®, a catalytically active gold nanocrystal suspension, as a potential disease-modifying therapy for amyotrophic lateral sclerosis (ALS).

SALT LAKE CITY, March 11, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biophar

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

SALT LAKE CITY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biophar

SALT LAKE CITY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharma

SALT LAKE CITY, Feb. 14, 2022 (GLOBE NEWSWIRE) --  Clene Inc. (NASDAQ: CLNN) along with its wholly owned subsidiary Clene Nanomedicine, Inc. (Clene) is a clinical-stage biopharmaceutical company fo

Steve Cohen’s Point72 Asset Management lost money in January, making it an outlier as several multistrategy hedge funds posted gains during a volatile start of the year for stocks.

Clene Inc (CLNN) shares closed today 15.2% lower than it did at the end of yesterday. The stock is currently down 26.6% year-to-date, down 57.6% over the past 12 months, and down 66.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.4%. Trading Activity Shares traded as high as $4.08 and as low as $2.96 this week.Shares closed 83.1% below its 52-week high and 1.7% above its 52-week low.Trading volume this week was 4.5% higher than the 10-day average and 28.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 4815.3% The company's stock price performance over the past 12 months lags the peer average by 260.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Clene Inc (CLNN) shares closed today at 1.7% above its 52 week low of $2.96, giving the company a market cap of $187M. The stock is currently down 26.6% year-to-date, down 57.6% over the past 12 months, and down 66.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 28.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 4815.3% The company's stock price performance over the past 12 months lags the peer average by 260.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Clene Inc (CLNN) shares closed 0.3% lower than its previous 52 week low, giving the company a market cap of $237M. The stock is currently down 6.8% year-to-date, down 48.0% over the past 12 months, and down 57.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 50.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -810.2% The company's stock price performance over the past 12 months lags the peer average by 217.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Equities analysts expect that Clene Inc. (NASDAQ:CLNN) will post earnings per share (EPS) of ($0.18) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Clenes earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.17). The company is scheduled to issue [] The post Zacks: Brokerages Anticipate Clene Inc. (NASDAQ:CLNN) Will Announce Earnings of -$0.18 Per Share appeared first on ETF Daily News .